Combining radiation therapy, chemo safely treats head and neck cancers

Subscribe to Oneindia News

Washington, Nov 04 (ANI): A new research has shown that stereotactic body radiotherapy (SBRT), a radiation therapy procedure pioneered at the University of Pittsburgh Cancer Institute (UPCI) that precisely delivers a large dose of radiation to tumors, may effectively control and treat head and neck cancers when combined with the chemotherapy Cetuximab, according to researchers from UPCI.

The study, led by Dwight E. Heron, M.D., professor of otolaryngology and vice chairman of the Department of Radiation Oncology at the University of Pittsburgh School of Medicine, enrolled 24 patients with recurrent head and neck cancers who had previously undergone radiation therapy treatment. Patients received Cetuximab a week before and during the two-week course of SBRT. The study showed that the regimen is a safe treatment option and may improve overall patient survival rates.

According to Heron, the study is important because surgical treatments for many patients with recurrent, locally advanced head and neck cancers are frequently limited, while other treatments either fail to adequately control the disease progression or are too toxic for patients to manage.

For this study, Heron and his team combined Cetuximab, which has been shown to enhance the effect of radiation therapy in patients with newly diagnosed head and neck cancers, and SBRT. By combining the two, treatment time was reduced from six weeks to one week while improving the side effects of re-treatment.

"We think this combination also may improve local control and perhaps survival rates, as we have seen in our own retrospective series. Most importantly, this study contributes to the emerging data fueled by UPCI suggesting a role for SBRT in patients with recurrent head and neck cancers," said Heron.

The results of the research has been presented at the American Society for Radiation Oncology (ASTRO) annual meeting in San Diego.(ANI)

Please Wait while comments are loading...